CRDF logo

Cardiff Oncology, Inc.

CRDF
Healthcare|Biotechnology|US
$0.80
+0.04 (+5.30%)
DCF Value
$0.03
Tangible Book / Share
$0.39
Cash / Share
$0.50
Next Earnings Report
Mar 4, 2027
EPS est. -$0.13 · Revenue est. $86.4K
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest Jul 16, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (3)

Dec 2026
Est. completion
P1P2Breast Cancer
Onvansertib + Paclitaxel In TNBC
NCT05383196n=50
Jun 2027
Est. completion
Early P1Locally Advanced Pancreatic Ductal Adenocarcinoma
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
NCT04005690n=90
Aug 2027
Est. completion
P2Small-cell Lung Cancer
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
NCT05450965n=37

Awaiting Results (3)

Trials past primary completion date but still active — data readout may be imminent.

Nov 2026
P2
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
NCT06106308
Jul 2026
P1P2
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
NCT06736717
Sep 2023
ARtificial Intelligence for Gross Tumour vOlume Segmentation
NCT05775068

Recent Press Releases

Cardiff Oncology to Participate in the UBS Global Biopharma Conference
Nov 3, 2026 · GlobeNewsWire
Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
Oct 27, 2026 · GlobeNewsWire
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
Oct 21, 2026 · GlobeNewsWire
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
Sep 14, 2026 · GlobeNewsWire
Cardiff Oncology to Participate in September 2026 Conferences
Sep 2, 2026 · GlobeNewsWire
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
Aug 11, 2026 · GlobeNewsWire

SEC Filings (55)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 27, 20268-KMaterial eventDocumentIndex
Oct 22, 20268-KMaterial eventDocumentIndex
Sep 14, 20268-KMaterial eventDocumentIndex
Aug 26, 2026DEFA14AProxy / shareholder voteDocumentIndex
Aug 26, 2026DEF 14AProxy / shareholder voteDocumentIndex
Aug 14, 2026PRE 14AProxy / shareholder voteDocumentIndex
Aug 11, 20268-KMaterial eventDocumentIndex
Aug 11, 202610-QQuarterly reportDocumentIndex
Jul 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 21, 2026S-8Employee stock planDocumentIndex
Jul 16, 20268-KMaterial eventDocumentIndex
Jul 16, 2026424B5Offering prospectusDocumentIndex
Jun 11, 20268-KMaterial eventDocumentIndex
Jun 3, 20268-KMaterial eventDocumentIndex
May 29, 20268-KMaterial eventDocumentIndex
May 19, 20268-KMaterial eventDocumentIndex
May 14, 20268-KMaterial eventDocumentIndex
May 14, 202610-QQuarterly reportDocumentIndex
Apr 23, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 23, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 23, 2026ARSAnnual report to holdersDocumentIndex
Apr 9, 20268-KMaterial eventDocumentIndex
Apr 2, 20268-KMaterial eventDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 25, 20268-KMaterial eventDocumentIndex
Feb 24, 20268-KMaterial eventDocumentIndex
Feb 24, 202610-KAnnual reportDocumentIndex
Jan 27, 20268-KMaterial eventDocumentIndex
Nov 6, 20258-KMaterial eventDocumentIndex
Nov 6, 202510-QQuarterly reportDocumentIndex
Aug 28, 2025S-8Employee stock planDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Jul 29, 20258-KMaterial eventDocumentIndex
Jul 29, 202510-QQuarterly reportDocumentIndex
Jul 29, 2025SC 13GPassive 5%+ stakeDocumentIndex
Jun 26, 20258-KMaterial eventDocumentIndex
Jun 17, 20258-KMaterial eventDocumentIndex
May 13, 2025EFFECTDocumentIndex
May 8, 2025S-3/AShelf registrationDocumentIndex
May 8, 20258-KMaterial eventDocumentIndex